Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Postoperative External Beam Radiotherapy for Retroperitoneal Soft Tissue Sarcoma

후복막 연조직 육종의 수술 후 외부 방사선 치료

  • Jang, Na-Young (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, Il-Han (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Choi, Jin-Hwa (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Park, Charn-Il (Department of Radiation Oncology, Seoul National University College of Medicine)
  • 장나영 (서울대학교 의과대학 방사선종양학교실) ;
  • 김일한 (서울대학교 의과대학 방사선종양학교실) ;
  • 최진화 (서울대학교 의과대학 방사선종양학교실) ;
  • 박찬일 (서울대학교 의과대학 방사선종양학교실)
  • Published : 2008.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the clinical outcomes and prognostic factors in retroperitoneal soft tissue sarcomas treated by postoperative radiotherapy. Materials and Methods: The records of 23 patients with retroperitoneal soft tissue sarcomas, who underwent postoperative radiotherapy between 1985 and 2003, were analyzed. The median follow-up period was 77 months (range, $8{\sim}240$ months). A total of 21 patients presented with primary disease, and two patients presented with recurrent disease. Liposarcomas and leiomyosarcomas represented 78% of the diagnosed tumor cases. Moreover, 17 cases were of high grade (grade 2 or 3). The median tumor size was 13 cm (range, $3{\sim}50\;cm$). Complete excision was achieved in 65% of patients. The median radiation dose was 50.4 Gy (range, 45.0 to 59.4 Gy), with conventional fractionation. Results: The 5-year overall, local recurrence-free, and distant metastasis-free survival rates were 68%, 58%, and 71%, respectively. Eleven patients experienced local recurrence, while 9 patients experienced distant metastasis. The most common site for distant metastasis was the liver. A univariate analysis revealed that adjacent organ invasion and age (>60 years) as the significant risk factors contributing to the prediction of poor overall survival. Moreover, multivariate analyses indicated that adjacent organ invasion remained significantly associated with a higher risk of death. In addition, patient age (>60 years) was the other identified risk factor for local recurrence by univariate and multivariate analyses. Except for one case of grade 3 diarrhea, no patient suffered grade 3 or higher complications. Conclusion: Our results were comparable to previous reports in that adjacent organ invasion and patient age (>60 years) were significant predictors of poor survival and tumor recurrence, respectively.

목 적: 수술 후 방사선 치료를 받은 후복막 연조직 육종 환자들의 치료 성적과 예후 인자를 분석해 보고자 하였다. 대상 및 방법: 1985년부터 2003년까지 수술 후 방사선 치료를 받은 후복막 연조직 육종 환자 23명의 자료를 분석하였다. 추적 관찰 기간은 8개월에서 240개월까지로 중앙값은 77개월이었다. 전체 환자 중 21명이 원발성 종양이었고, 두명은 재발성 이었다. 지방육종과 평활근육종이 전체 종양의 78%를 차지하였고 17명의 환자가 조직학적으로 고등급(2또는 3등급)이었다. 종양의 크기는 3에서 50 cm까지 분포하였으며 중앙값은 13 cm이었다. 65%의 환자에서 종양의 완전절제가 이루어졌다. 방사선치료는 일일 1.8에서 2.0 Gy를 주 5회 조사하여 총 45에서 59.4 Gy를 조사하였으며 중앙값은 50.4 Gy였다. 결 과: 환자들의 5년 전체생존율, 국소무재발생존율, 무전이생존율은 각각 68%, 58%, 71%였다. 11명의 환자에서 국소 재발이 일어났으며, 9명에서는 원격전이가 발생했다. 원격전이는 간에서 가장 많이 발생했다. 예후인자 분석 중 일변량 분석에서는 주변장기를 침윤한 경우와 60세를 초과한 나이가 생존율에 나쁜 영향을 주는 인자로 분석되었고 이중 주변장기를 침윤한 것은 다변량 분석에서도 유의한 인자로 분석되었다. 60세를 초과한 경우는 일변량과 다변량 분석 모두에서 국소재발에 유의한 영향을 미치는 인자였다. 한 명의 3등급의 설사를 제외하고는 3등급 이상의 치료에 의한 부작용은 보고되지 않았다. 결 론: 본 연구 결과 이전에 보고 되었던 다른 연구들의 결과와 비슷한 정도의 치료성적이 분석되었으며 주변 장기를 침범한 경우와 60세를 초과한 경우가 환자의 생존과 재발에 나쁜 영향을 미치는 유의한 인자였다.

Keywords

References

  1. Clark JA, Tepper JE. Role of radiation therapy in retroperitoneal sarcomas. Oncology (Williston Park) 1996;10:1867-1872; discussion 1872-1864
  2. Zlotecki RA, Katz TS, Morris CG, Lind DS, Hochwald SN. Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience. Am J Clin Oncol 2005;28:310-316 https://doi.org/10.1097/01.coc.0000158441.96455.31
  3. Catton CN, O'Sullivan B, Kotwall C, Cummings B, Hao Y, Fornasier V. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1994;29: 1005-1010 https://doi.org/10.1016/0360-3016(94)90395-6
  4. Heslin MJ, Lewis JJ, Nadler E, et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol 1997;15:2832-2839 https://doi.org/10.1200/JCO.1997.15.8.2832
  5. Karakousis CP, Velez AF, Gerstenbluth R, Driscoll DL. Resectability and survival in retroperitoneal sarcomas. Ann Surg Oncol 1996;3:150-158 https://doi.org/10.1007/BF02305794
  6. Gronchi A, Casali PG, Fiore M, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer 2004;100:2448-2455 https://doi.org/10.1002/cncr.20269
  7. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355-365 https://doi.org/10.1097/00000658-199809000-00008
  8. Fein DA, Corn BW, Lanciano RM, Herbert SH, Hoffman JP, Coia LR. Management of retroperitoneal sarcomas: does dose escalation impact on locoregional control? Int J Radiat Oncol Biol Phys 1995;31:129-134 https://doi.org/10.1016/0360-3016(94)E0302-Z
  9. Tepper JE, Suit HD, Wood WC, Proppe KH, Harmon D, McNulty P. Radiation therapy of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1984;10:825-830 https://doi.org/10.1016/0360-3016(84)90383-3
  10. Gilbeau L, Kantor G, Stoeckle E, et al. Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma. Radiother Oncol 2002;65:137-143 https://doi.org/10.1016/S0167-8140(02)00283-9
  11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655 https://doi.org/10.1097/00000421-198212000-00014
  12. Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 1984; 53:530-541 https://doi.org/10.1002/1097-0142(19840201)53:3<530::AID-CNCR2820530327>3.0.CO;2-D
  13. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346 https://doi.org/10.1016/0360-3016(95)00060-C
  14. Van Dalen T, Hoekstra HJ, van Geel AN, et al. Locoregional recurrence of retroperitoneal soft tissue sarcoma: second chance of cure for selected patients. Eur J Surg Oncol 2001;27:564-568 https://doi.org/10.1053/ejso.2001.1166
  15. Stoeckle E, Coindre JM, Bonvalot S, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 2001;92:359-368 https://doi.org/10.1002/1097-0142(20010715)92:2<359::AID-CNCR1331>3.0.CO;2-Y
  16. Bobin JY, Al-Lawati T, Granero LE, et al. Surgical management of retroperitoneal sarcomas associated with external and intraoperative electron beam radiotherapy. Eur J Surg Oncol 2003;29:676-681 https://doi.org/10.1016/S0748-7983(03)00139-2
  17. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859-868 https://doi.org/10.1200/JCO.1996.14.3.859
  18. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203 https://doi.org/10.1200/JCO.1998.16.1.197
  19. Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, Cance WG. Retroperitoneal soft tissue sarcoma. Cancer 2005;104:669-675 https://doi.org/10.1002/cncr.21264
  20. Ballo MT, Zagars GK, Pollock RE, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys 2007;67:158-163 https://doi.org/10.1016/j.ijrobp.2006.08.025
  21. Singer S, Corson JM, Demetri GD, Healey EA, Marcus K, Eberlein TJ. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 1995;221:185-195 https://doi.org/10.1097/00000658-199502000-00009
  22. Kim WD, Oh DH, Ha SW. Postoperative radiotherapy in the treatment of soft tissue sarcomas. J Korean Soc Ther Radiol 1995;13:69-78
  23. Greene F, Page D, Fleming I. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. New York: Springer-Verlag, 2002
  24. Van Dalen T, Hennipman A, Van Coevorden F, et al. Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma. Ann Surg Oncol 2004;11:483-490 https://doi.org/10.1245/ASO.2004.09.005
  25. Jones JJ, Catton CN, O'Sullivan B, et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Ann Surg Oncol 2002;9:346-354 https://doi.org/10.1007/BF02573869
  26. Pawlik TM, Pisters PW, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate-or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 2006;13:508-517 https://doi.org/10.1245/ASO.2006.05.035
  27. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359:2235-2241 https://doi.org/10.1016/S0140-6736(02)09292-9
  28. Fiveash JB, Hyatt MD, Caranto J, et al. Preoperative IMRT with dose escalation to tumor subvolumes for retroperitoneal sarcomas: initial clinical results and potential for future dose escalation. Int J Radiat Oncol Biol Phys 2002;54:140 https://doi.org/10.1016/S0360-3016(02)03299-6
  29. Tzeng CW, Fiveash JB, Popple RA, et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer 2006;107:371-379 https://doi.org/10.1002/cncr.22005